NCT04993027View on ClinicalTrials.gov

Topical Vancomycin for Infection Prophylaxis in TJA

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 30, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions
Infection of Total Hip Joint ProsthesisInfection of Total Knee Joint Prosthesis
Interventions
DRUG

Vancomycin Powder

Vancomycin is a bactericidal aminoglycoside antibiotic which inhibits cell wall synthesis. It is effective against gram positive bacteria. Though most commonly administered intravenously, it can be delivered orally or directly into surgical incisions and wounds in certain indications.

All Listed Sponsors
collaborator

University of Calgary

OTHER

lead

Alberta Hip and Knee Clinic

OTHER